An official website of the United States government
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Trial Status: active
This is a multi-center, open-label study to investigate the safety, tolerability,
pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245
administered orally on a once daily (QD) schedule in participants with unresectable,
locally advanced, or metastatic solid tumors.
Inclusion Criteria
18 years or older
Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
Eastern cooperative oncology group (ECOG) performance status ≤ 1
Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)
Exclusion Criteria
Received treatment with another RBM39 degrader
Clinically significant gastrointestinal (GI) or GI malabsorption
Additional locations may be listed on ClinicalTrials.gov for NCT06678659.
Locations matching your search criteria
United States
California
Duarte
City of Hope Comprehensive Cancer Center
Status: Active
Name Not Available
Ohio
Cleveland
Case Comprehensive Cancer Center
Status: Active
Name Not Available
Approximately 85 participants will be enrolled in this open-label Phase 1/2 study,
allocated 55 participants in Phase 1 and 10-30 participants in Phase 2. The purpose of
this study is to investigate the safety, tolerability and pharmacokinetics of REC-1245
for the treatment of participants with unresectable locally advanced or metastatic solid
tumors. Participants will receive treatment with REC-1245 for up to 2 years.
